341) The use of specific clinical treatment goals (e.g., two-hour pain free |
342) iol doses ≥ 1.5 mcg/day to meet current treatment goals. |
343) ificant main effect in the high vitamin D treatment group in VDAART. |
344) Studies were included if they had a treatment group with a mean age of 65 year |
345) ties are different or the sample sizes of treatment groups are unbalanced. |
346) ion of unbalanced sample sizes in the two treatment groups or large treatment effect |
347) entlessly for the single most efficacious treatment may indirectly diminish the numb |
348) lts suggest that long-term PARP inhibitor treatment may prime both BRCA1 mutant and |
349) is that readers may focus overly on what treatment ranks best and focus insufficien |
350) or to compare the intervals or ranges of treatment ranks. |
351) Mechanistically, adropin treatment reduced BBB damage, degradation |
352) No studies showed that antifungal treatment reduced mortality. |
353) m regulator of cell fate, plasticity, and treatment resistance in NEPC that can rev |
354) etect rare subclones possibly involved in treatment resistance. |
355) tential to help in prevention, diagnosis, treatment, screening, management, and cont |
356) demics in terms of prevention, diagnosis, treatment, screening, surveillance, resour |
357) may influence the future of brain injury treatment through modulation of neuroinfla |
358) rtially maintained following cessation of treatment through the duration of hypoxic |
359) t least one G allele, despite montelukast treatment, were increased (odds-ratio = 2. |
360) Successful treatments were reported at least in some |
361) italization and occurring during adjuvant treatment when patients are not burdened b |
362) significantly recovered by antiretroviral treatment when we compared 262 ART positiv |
363) mal prehabilitation program before cancer treatment ("prehabilitation" listed in key |
364) 'Universal' access to antiretroviral treatment (ART) has become the global stan |
365) known as to the effect of electric field treatment (EFT) on the lung. |
366) obtained before (pre-injection) and after treatment (i.e., at 2 and 6 months). |
367) als evaluating the effects of psychiatric treatment (n = 3) and probiotic interv |
368) mized to control or high DBI polypharmacy treatment (simvastatin, metoprolol, oxybut |
369) R47H heterozygous tauopathy mice, MK-2206 treatment abolished a tauopathy-dependent |
370) eosinophils in naïve mice within 2 h of treatment, accompanied by an increase in I |
371) rther, to gain traction on prevention and treatment, additional research to identify |
372) SC trastuzumab are equivalent in terms of treatment-emergent adverse events (TEAEs) |
373) nce it makes a compromise between optimal treatment allocation and randomness with s |
|